BUY Aurobindo Pharma — Manas Jaiswal, 17 Sept 2026

byManas JaiswalHorizon: NA (inferred Swing (≤2wk))17 Sept 2026via CNBC Awaaz.

Entry₹1,683.2Inferred

Target₹1,730

Stop loss₹1,669-0.84% risk

Exit₹1,730Target hit — time not yet verified

Target hit+2.78%0.00%upside left

Follow Manas Jaiswal for new calls(31% target hit, 306 closed calls)Get alerts Watch AUROPHARMA for new buy/sell callsGet alerts See 258 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 18 Sept, 3:53 pm IST

10 supporting1 neutral1 opposing

Supports the BUY call (10)

MACD above its signal line — bullish momentum

Technicals · macd·18 Sept · today

1 advisor has an active BTST BUY call on this stock, issued in the last 14 days

Advisor consensus · adjacent horizon·17 Sept · yesterday

JM Financial sees up to 28% upside in Dr Reddy’s and Aurobindo Pharma. Should you buy?

NewsEt-Markets·16 Sept · 2d ago

Aurobindo Pharma Gets First USFDA Nod For First Metered-Dose Inhaler

NewsNdtv-Profit·15 Sept · 2d ago

Aurobindo Pharma gets US FDA nod to sell first metered-dose asthma inhaler in US

NewsCnbc-Tv18·15 Sept · 3d ago

Neutral / worth noting (1)

Upcoming Stock Split, Dividend, Bonus Issue THIS Week: Aurobindo Pharma, Muthoot Finance, More | Full List

NewsGoogle News·5 Sept · 2w ago

Weighs against the BUY call (1)

1 advisor has an active short-term SELL call on this stock

Advisor consensus · adjacent horizon·6 Aug · 1mo ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.